Randomized Phase III Study of IV Rigosertib vs Best Supportive CARE (BSC) in Patients with Higher-risk MDS (HR-MDS) After Failure of Hypomethylating Agents (HMAs)

Guillermo Garcia-Manero, MD1, Pierre Fenaux, MD2, Aref Al-Kali, MD3, Maria R. Baer, MD4, Mikkael Sekeres, MD5, Gail Roboz, MD6, Gianluca Gaidano, MD7, Bart Scott, MD8, Peter Greenberg, MD9, Uwe Platzbecker, MD10, David P. Steensma, MD11, Suman Kambhampati, MD12, Karl-Anton Kreuzer, MD13, Lucy Godley, MD14, Robert Collins, Jr, MD15, Ehab Attallah, MD16, Nozar Azarnia, PhD17, Michael Petrone, MD17, Barbara Snyder, MA17, Lewis R. Silverman, MD18

1MD Anderson Cancer Center, Houston, TX, USA; 2Hospital St Louis, Paris, France; 3Mayo Clinic, Rochester, MN, USA; 4University of Maryland, Baltimore, MD, USA; 5Cleveland Clinic, Cleveland, OH, USA; 6Dana-Farber Cancer Institute, Boston, MA, USA; 7University of Kansas Medical Center, Westwood, KS, USA; 8Dana-Farber Cancer Institute, Boston, MA, USA; 9Stanford Medical School, Stanford, CA, USA; 10Universitätsklinikum Dresden, Dresden, Germany; 11Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 12Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 13University of Chicago Medical Center, Chicago, IL, USA; 14University of Texas, Southwest Medical Center at Dallas, Dallas, TX, USA; 15Froedtert Hospital and Medical College of Wisconsin, Milwaukee, WI, USA; 16Froedtert Hospital and Medical College of Wisconsin, Milwaukee, WI, USA; 17Onconova Therapeutics, Inc., Newtown, PA, USA; 18Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

INTRODUCTION

• After failure of HMAs, patients (pts) with HR-MDS have very poor prognosis, with a median survival of 6 months and no approved therapy options

• Rigosertib is a novel dual PI3K/PLK pathway inhibitor that targets the RAS binding domain of signaling proteins.

• ONTIME was the first Phase III, randomized, controlled study in pts after failure of HMAs.

METHODS

• Pts with HR-MDS (<30% bone marrow blasts) were randomly assigned 2:1 to receive rigosertib or best supportive care (BSC).

• Rigosertib was administered at 1800 mg/24 hr for 72 hr as a continuous intravenous (CIV) ambulatory infusion, every 2 weeks for the first 16 weeks, and then every 4 weeks.

• Primary endpoint was overall survival (OS).

• Analysis based on 242 deaths (80% maturity) with median follow-up of >18 months.

RESULTS

Patient Characteristics

The study enrolled 299 HR-MDS pts who had failed to respond to (25%), progressed on (37%), or relapsed after (38%) HMA treatment. Overall, the 2 arms were balanced in terms of baseline characteristics, with the majority of pts being male (66%), and White (82%). Median age was 74 years. The majority of pts (85%) had an Eastern Cooperative Oncology Group (ECOG) score of 0 or 1. The median duration of the last HMA therapy was 8.8 months (mo) for rigosertib and 10.3 mo for BSC.

Efficacy

No obvious differences between rigosertib and BSC were found in the incidence of AEs or of ≥ Grade 3 AEs (Table 2). Median dose intensity was 92%. Protocol-defined dose reductions were reported in 5% of pts, with 24% experiencing dose delays of >7 days, mostly due to unrelated adverse events (AEs). Rigosertib had low myelotoxicity in ONTIME, which is consistent with previous clinical experience. There were no significant compliance or operations issues related to the ambulatory continuous infusion.

Table 1. ONTIME Trial: Subgroups Correlated with Better Survival

<table>
<thead>
<tr>
<th>Subgroup</th>
<th>Rigosertib Median (mos)</th>
<th>BSC Median (mos)</th>
<th>Hazard Ratio (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary HMA failure</td>
<td>127.6</td>
<td>57.3</td>
<td>0.69</td>
<td>0.040</td>
</tr>
<tr>
<td>Duration of prior HMA &lt; 9 mos</td>
<td>103.7</td>
<td>46.4</td>
<td>0.55</td>
<td>0.003</td>
</tr>
<tr>
<td>Age &lt; 75 yrs</td>
<td>104.9</td>
<td>54.1</td>
<td>0.52</td>
<td>0.0004</td>
</tr>
<tr>
<td>Very high risk per IPSS-R</td>
<td>93.7</td>
<td>41.2</td>
<td>0.57</td>
<td>0.005</td>
</tr>
</tbody>
</table>

CONCLUSION

The primary endpoint of OS was not statistically significant in the ITT population, but rigosertib-related improvement in OS was noted in several subgroups of MDS pts, including those with “primary HMA failure” and those with Very High Risk per IPSS-R. Continuous IV therapy with rigosertib had a favorable safety profile in this orphan population of elderly pts with MDS. These results suggest that rigosertib is most effective in, and can be safely administered to, patients who might be expected to have the worst prognosis.

REFERENCES